近日,乐普生物发布了2025年上半年业绩预告,公司预计上半年将取得利润不少于2400万元,实现同比扭亏为盈。这是公司成立以来首次实现盈利。据乐普表示,能实现转亏为盈,主要得益于公司收入的大幅成长,其中主要包括与ArriVent BioPharma就MRG007开展的许可合作收入,以及普佑恒®(普特利单抗注射液)的销售收入增长。PD-1销售增长强势普特利单抗(普佑恒)仍是乐普唯一的的商业化产品,于...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.